A Clinical Study of Low-dose Radiotherapy Combined With Conventional Radiotherapy in Patients With Malignant Tumors After Immunotherapy Failure
Latest Information Update: 24 Sep 2022
At a glance
- Drugs Camrelizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Toripalimab (Primary)
- Indications Cancer
- Focus Therapeutic Use
Most Recent Events
- 24 Sep 2022 New trial record